We aim to highlight this potentially underreported adverse effect of BCR::ABL1 TKIs therapy and to propose a rational framework for the therapeutic management of those CML patients who develop BME during TKI therapy. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.